干扰素α-2b联合利巴韦林治疗慢性丙型肝炎72周疗效分析  

Evalluation of 72 weeks treatment with interferon plus ribavirin in patients with chronic hepatitis C

作　　者：李志勤[1] 武淑环[1] 孙长宇[1] 余祖江[1] 江河清[1] 

机构地区：[1]郑州大学第一附属医院感染科,450052

出　　处：《中国现代药物应用》2010年第11期16-17,共2页Chinese Journal of Modern Drug Application

摘　　要：目的评价慢性丙型肝炎抗病毒治疗疗程延长至72周疗效。方法将122例患者经知情同意分为治疗组(62例)和对照组(60例),均给予干扰素α-2b(安徽安科生物制品有限公司)5Mu联合利巴韦林抗病毒治疗,治疗组治疗72周,对照组治疗48周,均随访24周。观察两组的RVR、EVR、ETVR、SVR。结果治疗组的ETVR、SVR均高于对照组,二者差异有显著性(P<0.05),两组的RVR、EVR差异无统计学意义(P>0.05),治疗组基因2a型患者较1b型患者随访结束应答率高。结论延长慢性丙型肝炎患者抗病毒治疗疗程可提高抗病毒治疗SVR率,丙肝病毒基因2a型抗病毒治疗远期疗效优于基因1b型。Objective To evaluate the 72 weeks treatment with interferon plus ribavirin in patients with chronic hepatitis C. Methods 122 patients were divided into treatment group and control group, all of the patients were given interferon a-2b plus ribavirin treatment, the course of treatment for treatment group was 72 weeks and for the control group was 48 weeks, follow up 24 weeks to evaluate the two groups＇ rates of RVR, EVR,ETVR,SVR. Results The treatment group＇ s rates of ETVR,SVR were higher than that of the control group（P 〈0. 05）,there was no significant difference of RVR,EVR between the two groups（P 〉 0. 05 ））, the SVR rate of the that of the patients with genotype 2a was significantly higher than that of the patients with genotype 1 b. Conclusion Prolong the course of anti-virus treatment of chronic hepatitis C could increase the rate of SVR,the long-term therapeutic effects of patients with gene 2a are better than patients with gene 1b.

关 键 词：干扰素Α-2B 慢性丙型肝炎 抗病毒治疗 疗效分析 利巴韦林 丙肝病毒基因 b型患者 丙型肝炎患者 

分 类 号：R512.63[医药卫生—内科学]